Drugs / GenSci048
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07547995 | Jun 2026 → Dec 2027 expected | uveitis | Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06963177 | May 2025 → May 2028 expected | endometriosis | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci048 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07547995 ↗ |
| Route | Subcutaneous | “GenSci048 subcutaneously (SC) every 4 weeks.” NCT06963177 ↗ |